Recent Analysts’ Ratings Changes for Verastem (VSTM)

Verastem (NASDAQ: VSTM) has recently received a number of price target changes and ratings updates:

• 7/7/2026 – Verastem was given a new $14.00 price target by Royal Bank Of Canada. They now have an “outperform” rating on the stock.
• 7/2/2026 – Verastem had its “buy” rating reaffirmed by BTIG Research. They now have a $18.00 price target on the stock.
• 6/24/2026 – Verastem had its “outperform” rating reaffirmed by Royal Bank Of Canada. They now have a $15.00 price target on the stock.
• 6/24/2026 – Verastem had its “buy” rating reaffirmed by BTIG Research. They now have a $18.00 price target on the stock.
• 6/24/2026 – Verastem had its “buy” rating reaffirmed by HC Wainwright. They now have a $18.00 price target on the stock.
• 6/23/2026 – Verastem had its price target lowered by Jefferies Financial Group Inc. from $15.00 to $8.00. They now have a “buy” rating on the stock.
• 6/20/2026 – Verastem was downgraded by Wall Street Zen from “hold” to “sell”.
• 6/17/2026 – Verastem was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 5/26/2026 – Verastem was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.

Insider Activity at Verastem

In other news, CEO Dan Paterson sold 20,871 shares of the business’s stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $4.18, for a total transaction of $87,240.78. Following the sale, the chief executive officer directly owned 591,242 shares of the company’s stock, valued at $2,471,391.56. The trade was a 3.41% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 1.94% of the company’s stock.

Verastem Oncology, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapies that target cancer stemness and resistance pathways. Established in 2010 and headquartered in Needham, Massachusetts, Verastem Oncology applies a precision-medicine approach to identify key signaling nodes responsible for tumor growth and relapse, with an emphasis on hematologic malignancies and solid tumors. The company’s research platform integrates insights into complex signaling networks to advance novel compounds from early discovery through clinical proof of concept.

The company’s lead marketed product is COPIKTRA (duvelisib), an oral inhibitor of PI3K-delta and PI3K-gamma, which received U.S.